Association between ease of suppression of ventricular arrhythmia and survival.
BACKGROUND
We tested the hypothesis that patients whose ventricular arrhythmias are easy to suppress have a lower rate of arrhythmic death, defined as arrhythmic death and nonfatal cardiac arrest, the primary end point in the Cardiac Arrhythmia Suppression Trials (CAST-I and CAST-II), than patients whose ventricular arrhythmias are hard to suppress. In addition, we evaluated the association between ease of suppression of ventricular arrhythmias and mortality of all causes.


RESULTS
CAST-I investigated the effect on arrhythmic death of ventricular premature depolarization (VPD) suppression achieved by three drugs, encainide, flecainide, and moricizine, at two different dose levels; CAST-II investigated the same effect, using moricizine alone at three dose levels. If suppression was achieved, patients were randomized to the effective active drug or corresponding placebo. To examine the independence of easily suppressed ventricular arrhythmias as a predictor of arrhythmic death, we adjusted statistically for other variables that were related both to ease of suppression and arrhythmic death. Patients with ventricular arrhythmias (n = 1778) that were easy to suppress had fewer arrhythmic deaths during follow-up than those with ventricular arrhythmias that were hard to suppress (n = 1173) (relative risk, .59; P = .003). Patients whose VPDs were easily suppressed were older and had a lower frequency of prior history of heart failure and myocardial infarction. They also had a higher incidence of anterior myocardial infarction, VPD frequency, and average ejection fraction. After adjusting for these variables, we found that easily suppressed ventricular arrhythmias were still significant predictors of arrhythmic death (relative risk, .66; P = .013).


CONCLUSIONS
This study shows that the ease of VPD suppression identifies a subgroup of postmyocardial infarction patients who have low risk of arrhythmic death.
Goldstein
S
S
Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI 48202.
Brooks
M M
MM
Ledingham
R
R
Kennedy
H L
HL
Epstein
A E
AE
Pawitan
Y
Y
Bigger
J T
JT
D000368:Aged; D018592:Cross-Over Studies; D016700:Encainide / Q000627:therapeutic use*; D005424:Flecainide / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D016293:Moricizine / Q000627:therapeutic use*; D012307:Risk Factors; D014693:Ventricular Fibrillation / Q000188:drug therapy* / Q000401:mortality
D016293:Moricizine; D005424:Flecainide; D016700:Encainide